– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – SAN DIEGO, June 17, 2025 (GLOBE ...

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxicity profile – SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinica ...

Core Viewpoint - Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Cardiff Oncology suggest an improvement in the company's underlying business, potentially leading to higher stock prices [5]. Recent Earnings Estimate Revisions - For the fiscal year ending December 2025, Cardiff Oncology is expected to earn -$0.82 per share, reflecting a 13.7% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Cardiff Oncology has increased by 13.1%, indicating a positive trend in earnings expectations [8]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Cardiff Oncology to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].

Core Insights - The article discusses the process of identifying potential investment opportunities in the healthcare sector, particularly focusing on biotech and life-saving therapies [2]. Group 1: Investment Strategy - The investment strategy involves creating a high-priority watch list of ten companies within the healthcare sector, emphasizing innovative firms that are developing breakthrough therapies and pharmaceuticals [2]. - The author highlights a target-rich environment for finding candidate tickers to add to investment portfolios, indicating a robust market for healthcare investments [2]. Group 2: Analyst's Position - The analyst has disclosed a beneficial long position in the shares of IBRX and PFE, indicating confidence in these companies' future performance [3]. - There is an intention to potentially enter a long position in CRDF within the next 72 hours, suggesting ongoing evaluation of investment opportunities [3].

Cardiff Oncology (CRDF) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -5.26%. A quarter ago, it was expected that this molecular diagnostic company would post a loss of $0.25 per share when it actually produced a loss of $0.21, delivering a surprise of 16%.Over the last four quarters, the c ...

Cardiff Oncology First Quarter 2025 Financial Results and Business Update [Business Update and Highlights](index=1&type=section&id=Business%20Update%20and%20Highlights) Cardiff Oncology reported significant progress in its lead program for onvansertib, successfully completing enrollment for its Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer (mCRC) - Successfully completed enrollment in the randomized Phase 2 CRDF-004 trial, which evaluates onvansertib plus standard of care for first-line RAS-mutated mCRC[3](index=3&type=chunk)[4](index=4&type=chunk)[5](index=5&type=chunk) - Expanded its intellectual property with a second U.S. patent (**No. 12,263,173**) for onvansertib, covering its use with bevacizumab in all mCRC patients (both RAS-mutated and wild-type) across any line of therapy, with an expiration date of no earlier than **2043**[3](index=3&type=chunk)[5](index=5&type=chunk)[6](index=6&type=chunk) - The company expects to report additional clinical data from the ongoing CRDF-004 trial in the first half of 2025[4](index=4&type=chunk) [First Quarter 2025 Financial Results](index=2&type=section&id=First%20Quarter%202025%20Financial%20Results) For the first quarter of 2025, Cardiff Oncology reported cash, cash equivalents, and short-term investments of $79.9 million, with a projected cash runway into Q1 2027 Liquidity and Cash Flow (Q1 2025) | Metric | Value | Note | | :--- | :--- | :--- | | Cash, Equivalents & Investments | $79.9 million | As of March 31, 2025 | | Projected Cash Runway | Into Q1 2027 | Based on current projections | | Net Cash Used in Operations | $12.8 million | Increase of $5.1M from $7.7M in Q1 2024 | Operating Expenses (Q1 2025 vs Q1 2024) | Period | Total Operating Expenses | Change (YoY) | | :--- | :--- | :--- | | Q1 2025 | $14.5 million | +$3.4 million | | Q1 2024 | $11.1 million | - | - The increase in operating expenses was primarily driven by costs associated with the CRDF-004 clinical trial, other clinical programs, and professional fees for strategic advisory services[9](index=9&type=chunk) [Company Overview and Forward-Looking Statements](index=2&type=section&id=Company%20Overview%20and%20Forward-Looking%20Statements) Cardiff Oncology is a clinical-stage biotechnology company focused on developing cancer therapies by inhibiting PLK1, with its lead asset being onvansertib - Cardiff Oncology is a clinical-stage biotech company leveraging PLK1 inhibition to develop novel therapies for a range of cancers[10](index=10&type=chunk) - The lead asset, onvansertib, is being evaluated in clinical programs for RAS-mutated mCRC, mPDAC, SCLC, and TNBC[10](index=10&type=chunk) - The press release contains forward-looking statements subject to risks and uncertainties, including those related to clinical trials, financing, and regulatory approvals, as detailed in the company's SEC filings[11](index=11&type=chunk)[12](index=12&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents the company's financial position and performance, detailing the condensed statements of operations and balance sheets for the first quarter of 2025 [Condensed Statements of Operations](index=4&type=section&id=Condensed%20Statements%20of%20Operations) For the first quarter ended March 31, 2025, Cardiff Oncology reported a net loss of $13.4 million, or ($0.20) per share, compared to a net loss of $10.0 million, or ($0.22) per share, for the same period in 2024 Q1 2025 vs. Q1 2024 Statement of Operations (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Royalty revenues | $109 | $205 | | Research and development | $10,477 | $8,008 | | Selling, general and administrative | $4,014 | $3,130 | | **Total operating expenses** | **$14,491** | **$11,138** | | **Loss from operations** | **($14,382)** | **($10,933)** | | **Net loss** | **($13,434)** | **($10,011)** | | **Net loss per common share** | **($0.20)** | **($0.22)** | [Condensed Balance Sheets](index=5&type=section&id=Condensed%20Balance%20Sheets) As of March 31, 2025, the company's total assets were $84.8 million, down from $97.2 million at year-end 2024, primarily due to a decrease in cash and cash equivalents Balance Sheet Highlights (in thousands) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $24,095 | $51,470 | | Short-term investments | $55,792 | $40,276 | | **Total Assets** | **$84,807** | **$97,190** | | **Total Liabilities** | **$13,931** | **$14,241** | | **Total Stockholders' Equity** | **$70,876** | **$82,949** |

Core Insights - Cardiff Oncology, Inc. reported financial results for Q1 2025, highlighting progress in clinical trials and intellectual property expansion [1][4][6] Financial Performance - As of March 31, 2025, the company had approximately $79.9 million in cash, cash equivalents, and short-term investments [6][9] - Net cash used in operating activities for Q1 2025 was approximately $12.8 million, an increase of about $5.1 million from $7.7 million in Q1 2024 [6][11] - Total operating expenses for the three months ended March 31, 2025, were approximately $14.5 million, up from $11.1 million in the same period in 2024 [11][16] - The net loss attributable to common stockholders for Q1 2025 was $13.4 million, compared to a net loss of $10.0 million in Q1 2024 [16] Clinical Development - The company completed enrollment in the Phase 2 CRDF-004 trial for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) [2][10] - The trial involved 41 clinical sites in the U.S. and evaluated onvansertib in combination with standard of care therapies [10] - Additional clinical data from the ongoing CRDF-004 trial is expected in the first half of 2025 [3] Intellectual Property - Cardiff Oncology expanded its intellectual property portfolio with the issuance of a second patent covering the treatment of mCRC for bev-naïve patients [5][9] - The new U.S. patent No. 12,263,173 is set to expire no earlier than 2043 and covers the use of onvansertib in combination with bevacizumab across all lines of therapy for mCRC patients [5][9] Future Outlook - The company believes its current cash resources are sufficient to fund operations into Q1 2027 [7][9]

Table of Contents For the transition period from to COMMISSION FILE NUMBER 001-35558 CARDIFF ONCOLOGY, INC. (Exact Name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 27-2004382 (State or other juris ...

Group 1 - Cardiff Oncology (NASDAQ: CRDF) is emerging as a notable player in the colorectal cancer (CRC) biotech sector, with promising results from their randomized phase 2 trial [1] - The company has demonstrated significant potential in addressing CRC, which is a critical area in oncology [1] Group 2 - The article emphasizes the importance of understanding the science behind biotech investments to make informed decisions [1]

Core Viewpoint - Cardiff Oncology is expected to report a year-over-year increase in earnings despite lower revenues, with the actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate indicates a quarterly loss of $0.19 per share, reflecting a year-over-year change of +13.6% [3]. - Revenues are projected to be $0.17 million, down 19.1% from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 9.52% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Cardiff Oncology is higher than the Zacks Consensus Estimate, leading to an Earnings ESP of +24.32% [10][11]. Earnings Surprise Prediction - A positive Earnings ESP is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [8]. - Cardiff Oncology currently holds a Zacks Rank of 2, suggesting a high likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Cardiff Oncology was expected to post a loss of $0.25 per share but delivered a loss of $0.21, resulting in a surprise of +16% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Conclusion - Cardiff Oncology is positioned as a compelling earnings-beat candidate, but investors should consider other factors influencing stock performance beyond earnings results [16].